原发性肝癌介入治疗的研究现状

原发性肝癌(HCC)是最常见的恶性肿瘤,是严重威胁人类健康的恶性肿瘤之一。手术切除是HCC的首选治疗方式,但是仅有20%³0%的患者可行手术切除治疗。肝动脉化疗栓塞术(TACE)是已失去手术机会的HCC患者的一线治疗手段,与系统性全身化疗相比,TACE的不良反应较小,并且可联合其他治疗手段(分子靶向药物、载药微球、高强度聚焦超声等)进一步提高疗效。

The Current Status of Interventional Therapy of Hepatocellular Carcinoma

Hepatocellular carcinoma（ HCC）, a malignant tumor, is the most common primary liver cancerwhich seriously threatens human health. The optimal treatment of hepatocellular carcinoma is operation resec-tion, which is only feasible in 20%-30% of all the patients. Transcatheter arterial ehemoembolization （TACE）is the first-line therapy for the patients who have lost operation opportunity, the effect of which can be furtherimproved if combined with various treatments （ high intensity focused ultrasound, drug beating microsphere,molecular targeted drugs, etc. ）. Compared with systemic chemotherapy, TACE has less side effects.